You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development and validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 103

    Project Summary Sanfilippo disease (mucopolysaccharidosis type III; MPS III) is a devastating neurodegenerative lysosomal storage disorder of childhood whose pathologic features are neurologic: slowing of development, severe behavioral problems, progressive cognitive decline, dementia, and decline in motor skills leading to immobility, unresponsiveness, and death. We have focused on MPS IIID cause ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Arenavirus Antiviral Lead Optimization

    SBC: ARISAN THERAPEUTICS INC            Topic: NIAID

    DESCRIPTION provided by applicant Arenaviruses comprise a diverse family Several species are associated with severe arenaviral hemorrhagic fever AVHF in humans that exhibit case fatality rates as high as Human infection with arenaviruses typically occurs through contact with materials contaminated with the excretions of an infected rodent although direct human to human transmission may ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Arrayed drug microinjection for guiding precision medicine in relapsed lymphoma

    SBC: PRESAGE BIOSCIENCES, INC.            Topic: 102

    DESCRIPTIONprovided by applicantImprovements in cancer diagnostics and therapeutics have positively impacted outcomes for oncology patients within select clinical nichesHoweversignificant therapeutic uncertainty awaits the majority of today s oncology patients who present in the clinic with cancer that will relapse after exhibiting an initial response or whose cancer is already refractory to stand ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Advanced morphological analysis of cerebral blood flow for acute concussion diagnosis and return to play determination

    SBC: Neural Analytics, Inc.            Topic: 101

    Project Summary Abstract Between and million people each year suffer a mild TBI in the US alone Reliable diagnosis and prompt treatments are vital to managing the often serious short and long term sequelae resulting from mild TBI However a reliable objective and accurate method for mild TBI diagnosis outside of a hospital setting and in particular for determining RTP readiness has e ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. MicroRNA-based Radiation Biodosimeter (MiRAD) Phase II

    SBC: CHROMOLOGIC LLC            Topic: NIAID

    Abstract In response to PA-15-065, the broad long-term goal of this project is to develop a portable radiation biodosimeter to be used at the point-of-care (POC) for assessing precise radiation exposure and susceptibility for acute radiation syndrome (ARS) within the first 7 days of exposure starting with ~250 µL of blood collected from a finger stick and a turnaround time (TAT) of less than 40 m ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis

    SBC: Epigen Biosciences, Inc.            Topic: 400

    SummaryThe ultimate goal of our project is to develop novel therapeutics effective in chronic kidney diseases, such as diabetic nephropathy (DN), that normally develop fibrosis, lead to end stage renal disease and require renal replacement therapy. DN is a complication of diabetes and is characterized by thickening of the glomerular basement membrane and mesangial expansion, with progression into ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Near patient molecular diagnostics test for infections

    SBC: GeneFluidics, Inc.            Topic: R

    ABSTRACT Currentlythere are no FDA cleared molecular based tests for urinary tract infectionUTIpathogen identification and antimicrobial susceptibility testing to replace the andapos gold standardandaposof dipstick urinalysis and urine culturingAll pathogen identification tests still rely on clinical isolates from urine cultureslargely unchanged from Kochandapos s postulates developed in theth cen ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Molecular Diagnostic Test for Early Onset of Lyme disease

    SBC: Bioscience Development Inc            Topic: NIAID

    Project Summary/Abstract There is no validated assay to reliably detect the early onset of the Lyme disease infection at the time when antibiotic therapy has the best chance of a cure without sequelae. Diagnosis is often difficult because most symptoms are often nebulous, with the telltale “bulls-eye” rash only appearing and clearly recognizable in approximately half of cases. The standard typ ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain

    SBC: AFASCI, INC.            Topic: NINDS

    7. PROJECT SUMMARY Neuropathic pain remains a poorly managed medical condition affecting more than 1.5 billion people worldwide. Over 20 million people suffered from diabetic neuropathy and neuropathic pain in the US alone in 2015. The current standard of care is insufficient. Topical applications and systemic treatment with existing analgesics, including opioids, leave millions suffering. More th ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Phase IIB: Exploratory Clinical trials for The V Needle

    SBC: HEMOTEK            Topic: 400

    Hemodialysis (HD) is generally perceived as a safe, benign, procedure. But if venous needle dislodgement (VND) occurs during dialysis and the machine fails to detect it, within minutes the blood loss can be catastrophic, and even fatal. It is estimated that 400 dialysis patients suffer a dislodgement episode every week in the US. [3] In a Phase I/Phase II SBIR partnership with our clinical and med ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government